How to Buy Sellas Life Sciences Group Stock
Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc. , a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States.
Sellas Life Sciences Group stock last closed at $1.62, up 1.89% from the previous day, and has increased 39.66% in one year. It has overperformed other stocks in the Biotechnology industry by 1.01 percentage points. Sellas Life Sciences Group stock is currently +109.84% from its 52-week low of $0.77, and -28.6% from its 52-week high of $2.27.
As of Aug 5, 2025, there are 99.78M SLS shares outstanding. The market capitalization of SLS is $161.64M. In the past 24 hours, 1.12M SLS shares were traded.
How to Buy Sellas Life Sciences Group Stock
Not sure how to invest in Sellas Life Sciences Group stock? Here's how.
- Choose where to buy Sellas Life Sciences Group stock: You need to choose a stock brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you figure out where to buy Sellas Life Sciences Group stock.
- Sign up for a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit funds into your investment account: Select your method of payment and add your details.
- Research Sellas Life Sciences Group stock: The Sellas Life Sciences Group ticker symbol is SLS. Is Sellas Life Sciences Group stock a good investment? Should you buy shares of SLS? How do SLS's underlying business fundamentals look? Do top analysts think Sellas Life Sciences Group is a good buy? Why has SLS's stock price moved recently? (Hint: Our stock market research website can help you decide if SLS is a good stock to buy).
- Place your SLS purchase: Decide if you will purchase SLS shares at the current market price or use a limit order to buy SLS shares at a particular price.
- Get the latest news on your investment in SLS: Create a watchlist to get the latest news on your position in Sellas Life Sciences Group stock.
Step 1: Choose where to buy Sellas Life Sciences Group stock
You need an online brokerage account to access the NASDAQ market and buy SLS shares.
Our preferred brokerage: eToro
Based on our experience, eToro is the best online stock brokerage. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world markets: From Technology to Energy, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro offers a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've selected the right brokerage, you need to fill out some personal details so you can buy SLS stock today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to open a new brokerage account.
- Submit your details by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have filled out your info on one of the most highly reviewed stock trading apps, your next step is to transfer the money for your investment:
Watch the video below for more details depositing funds into your investment account.
Step 4: Research Sellas Life Sciences Group stock
Once you have figured out the best place to buy Sellas Life Sciences Group stock, it's important to evaluate their stock prior to investing, so you actually understand the risk as well as the upside.
Sellas Life Sciences Group Metrics
Fundamentals of Sellas Life Sciences Group
WallStreetZen was created to help everyday investors do more in-depth fundamental analysis.
You can view all of the due diligence checks on SLS's stock page.
How is SLS stock valued?
You can use many financial metrics, analyses, models, and charts to gauge SLS's true value.
Using relative valuations measures:
- SLS may be overvalued based on its P/B ratio of 5.82x, relative to Biotechnology industry P/B ratio of 4.26x
You can access more valuation analysis on SLS's stock here.
A look at SLS Cashflows and Balance Sheet
Passed Health Checks:
- SLS has a low debt to equity ratio of 0.26.
- There are more short-term assets than short-term liabilities on the SLS balance sheet.
- There are more short-term assets than long-term liabilities on the SLS balance sheet.
- Total SLS debt is lower than 5 years ago, relative to shareholder equity.
Failed Health Checks:
- SLS has $28.50M in cash and short term investments. This is not enough to cover its annual cash burn of $33.71M.
- SLS has cash burn of 33711000. It does not have sufficient cash and short-term investments to cover this.
Is it a good time to buy Sellas Life Sciences Group stock, according to Wall Street analysts?
Out of 1 sell side analysts who track SLS, the consensus analyst rating on Sellas Life Sciences Group is a Strong Buy
Please note that analyst ratings are not recommendations, nor are they investment advice.
You can dive deeper into what analysts are projecting on the Sellas Life Sciences Group stock forecast page.
SLS Technical Indicators
SLS Revenue
Last year, SLS revenue was $0.00. Over the past 4 year, SLS's revenue has gone up by -100% per year. This was slower than the Biotechnology industry average of 46%.
Learn more about SLS's earnings and revenue performance here.
Who is buying/selling SLS?
In the last 12 months, executives and large shareholders at SLS have bought more shares than they have sold.
Nostrand Robert L. Van, Director of SLS, was the latest SLS insider to buy. They bought $14,800.00 worth of SLS stock on Jun 12, 2025.
Learn more about who owns SLS shares here.
Does SLS stock generate passive income?
No, Sellas Life Sciences Group doesn't provide an income stream by paying out dividends.
Get analysis from other investors
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Place your SLS purchase
You have two main options:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are usually the easiest way to buy. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a particular price limit, place a limit order.
Click the Open button and your broker will execute the order.
If you require additional help with buying stocks on eToro, watch the helpful video below:
Step 6: Get the latest news on your investment in SLS
Now that you own some SLS stock, you'll want to stay up-to-date on your new shares.
Add SLS to a watchlist to track the most important metrics related to your SLS stock.
SLS Feed
How to Buy Stock in Sellas Life Sciences Group
To reiterate, here are the 6 steps for buying Sellas Life Sciences Group stock:
- Choose where to buy Sellas Life Sciences Group stock
- Sign up for a brokerage account
- Deposit funds into your investment account
- Research Sellas Life Sciences Group stock
- Place your SLS purchase
- Get the latest news on your investment in SLS
If you need a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to get the latest news on your new investment in Sellas Life Sciences Group, click below.
Related Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.